0.25Open0.25Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover162.97%IV40.26%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.0738Delta0.0218Gamma65.28Leverage Ratio-0.0208Theta-0.0008Rho-4.82Eff Leverage0.0055Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet